彭耀进，中国科学院动物研究所，北京干细胞与再生医学研究院，致一研究员。北京干细胞与再生医学研究院科技伦理研究中心主任、商务法务主任，中国科学院大学存济医学院讲习教授、中国科学院大学人文学院硕士生导师。生命科学学士、法学博士（Maastricht University, Netherlands）；主要研究领域包括生物技术法律与伦理，知识产权与标准，科技政策与管理；研究成果以第一作者或/和通讯作者在Nature Biotechnology (2x), Cell Stem Cell, Protein & Cell, Cell Proliferation等国内外权威学术期刊发表论文20余篇，皆为交叉学科研究成果；曾任欧洲共同法研究院博士研究员、马斯特里赫特大学全球化和国际规则研究所研究员、欧洲知识产权研究机构联盟第17届会议学术团队顾问；曾访问新加坡管理大学（Singapore Management University, SMU）法学院从事研究工作6个月。主持国家级、省部级等项目多项，包括国家重点研发计划专项子课题、中国科学院A类战略性先导科技专项子课题、中国科协“科技治理”年度重点课题等；2021年入选“中国科学院青年创新促进会”，同年被评为中国细胞生物学学会干细胞分会“干细胞社会公益先进个人”。

　　研究兴趣：生命科技领域法律与伦理、知识产权与标准、科技政策与管理等，例如干细胞与再生医学、基因编辑、合成生物学、脑机接口等领域。

教学课程：

　　生物医学法律与伦理（中国科学院大学，研究生课程）。

1. Lulu Ding, Zhenyu Xiao, Xia Gong，Yaojin Peng^*, Knowledge Graphs of Ethical Concerns of Cerebral Organoids, Cell Proliferation, 2022 (IF 6.831, SCI) (accepted)
2. Yaojin Peng^*, Jianwei Lv, Zhenyu Xiao, Lulu Ding, Qi Zhou^*, A framework for the responsible reform of the 14-day rule in human embryo research, Protein & Cell, published online: 15 Feb. 2022. (IF 14.870, SCI)
3. Jiani Cao, Jie Hao, Lei Wang, Yuanqing Tan, Yuchang Tian, Shiyu Li, Aijin Ma, Boqiang Fu, Jianwu Dai, Peijun Zhai, Peng Xiang, Yong Zhang, Tao Cheng^*, Yaojin Peng^*, Qi Zhou^*, Tongbiao Zhao^*. Developing standards to support the clinical translation of stem cells, STEM CELLS Transl Med. 2021; 10(S2): S85- S95. (IF: 6.940, SCI)
4. Miao Yu, Wei Lei, Jiani Cao, Lei Wang, Aijin Ma, Zhen-Ao Zhao, Huang-Tian Yang, Zhenya Shen, Feng Lan, Feng Cao, Ping Liang, Xuetao Pei, Andy Peng Xiang, Junying Yu, Yu Zhang, Yong Zhang, Qiyuan Li, Jiaxi Zhou, Jun Wei, Yaojin Peng, Huanxin Zhu, Lingmin Liang, Nan Cao, Boqiang Fu*, Jie Hao*, Tongbiao Zhao*, Shijun Hu*. Requirements for human cardiomyocytes. Cell Prolif. 2021; 00:e13150. (IF 6.831, SCI)
5. Yaojin Peng^*, Xiaoru Huang, Qi Zhou^*, Ethical and Policy Considerations for Human Embryo and Stem Cell Research in China, Cell Stem Cell, 2020, 27(4). (IF 20.860, SCI)
6. Jianwei Lv^#, Yeyang Su^#, Lingqiao Song, Xia Gong, Yaojin Peng^*, Stem cell ‘therapy’ advertisements in China: infodemic, regulations and recommendations, Cell Proliferation, 2020, 53(12). (IF 6.831, SCI)
7. Yaojin Peng^*, Patenting Human Embryonic Stem Cell Related Inventions in China: A Comparative Perspective, PhD thesis (Faculty of Law, Maastricht University, Netherlands, September 2018)
8. Yaojin Peng^*, The Patentability of Human Embryonic Stem Cell Technology in China, Nature Biotechnology, 2016, 34(1). DOI:10.1038/nbt.3417. (IF 43.113, SCI)
9. Yaojin Peng^*, The Morality and Ethics Governing CRISPR-Cas9 Patents in China, Nature Biotechnology, 2016, 34(6). DOI:10.1038/nbt.3590. (IF 43.113, SCI)
10. Yaojin Peng^*, Patent Term Extension in the Pharmaceutical Sector: An Asian Comparative Perspective, in The Future of Asian Trade Deals and IP (Kung-Chung Liu ed., Hart Publishing, forthcoming in 2019).
11. Yaojin Peng, UW-Google Intermediary Liability Research Project: Privacy Protection in China, available at https://www.law.uw.edu/media/1404/china-intermediary-liability-of-isps-privacy.pdf.
12. Nguyen Xuan-Thao, Trademark apologetic justice: China’s trademark jurisprudence on reputational harm. in Foreign scholars on Chinese law series: intellectual property law (translated into Chinese by Yaojin Peng^*), in Intellectual Property Law of China, Encyclopedia of China Publishing House, 2018).
13. Yaojin Peng^*，Jianwei Lv，The challenges and solutions of the 14-day rule in human embryo research（人类胚胎研究“14天规则”的挑战与出路）, Journal of Dialectics of Nature《自然辩证法通讯》, 2022 (accepted) (CSSCI )
14. Yaojin Peng, Qi Zhou^*，China’s Strategies for Governance of Biotechnological Changes and New Ethical Challenges（应对生物技术变革与伦理新挑战的中国方略）, Bulletin of Chinese Academy of Sciences（中国科学院院刊）, 2021,36(11):1288-1297. （CSCD，中文核心）
15. Yaojin Peng^*, The Era of Synthetic Biology: Biosafety, Biosecurity and Governance（合成生物学时代：生物安全、生物安保与治理），Journal of International Security Studies（国际安全研究），2020, 38(5): 29-57.（CSSCI）
16. Yaojin Peng^*, Li Wei, Ethical issues and the governance of life science and technology: A case study on human-animal chimeras（生命科技伦理问题与治理策略——以人-动物嵌合体研究为例）, Science & Technology Review（科技导报），2020, 38(5): 42-49.（中文核心）
17. Qi Zhou^*, Yaojin Peng, The Era of Biotechnology and Biosafety（这是生物技术的时代，也是生物安全的时代）, Journal of Engineering Studies（工程研究——跨学科视野中的工程），2020, 12(1).（CSCD，中文核心）
18. Yaojin Peng^*，Designer baby: How to face it（“设计婴儿”：我们将怎样面对）, Frontier Science（前沿科学）, 2019(3): 93-96.
19. Yaojin Peng^*, Intellectual Property Protection Concerning Stem Cell Research in China: Predicament and Solutions（中国干细胞知识产权保护的困境与对策）, Chinese Bulletin of Life Science（生命科学）, 2016, 28(8).（CSCD、北大核心）
20. Yaojin Peng^*, Employees’ Invention Compensation Regime in the Netherlands and Its Enlightenment to China（荷兰职务发明奖酬制度及其借鉴意义）, Journal of Fujian Jiangxia University（福建夏学院学报）, 2017, 7(4): 29-38.
21. Yong Wan, Jie Wang, Tianxiang He, Yaojin Peng, Zijiao Cheng, The Protection of Privacy in China（中国的隐私保护）, Journal of Shantou University （汕头大学学报）, 2017, 33(11) .